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Abstract
Background: The neurological complications of HIV infection remain poorly understood. Clinically, in vivo 1H
magnetic resonance spectroscopy (MRS) demonstrates brain injury caused by HIV infection even when the MRI
is normal. Our goal was to undertsand the dynamics of cerebral injury by performing a longitudinal in vivo 1H MRS
study of the SIV/macaque model of neuroAIDS.
Results: Eight rhesus macaques were infected with SIVmac251 and serially imaged with MRI and 1H MRS to
terminal AIDS or the endpoint of 2 years. During acute infection, there were stereotypical brain MRS changes,
dominated by a significant elevation of the Cho/Cr ratio in the frontal cortex. Subsequently, brain metabolic
patterns diverged between animals. There was an elevation of basal ganglia Cho/Cr four weeks post-inoculation
in 2 animals that developed SIV encephalitis (p = 0.022). Metabolite ratios averaged across all 8 animals were not
significantly different from baseline at any time point after 2 weeks post inoculation. However, linear regression
analysis on all 8 animals revealed a positive correlation between a change in frontal lobe Cho/Cr and plasma viral
load (P < 0.001, R = 0.80), and a negative correlation between NAA/Cr in the basal ganglia and the plasma viral
load (P < 0.02, R = -0.73). No MRI abnormalities were detected at any time.
Conclusions:  After infection with SIV, macaque brain metabolism changes in a complex manner that is
dependent on brain region, host factors and viral load. An elevation of basal ganglia Cho/Cr 4 weeks after SIV
infection may be marker of a propensity to develop SIV encephalitis. Elevations of Cho/Cr, often observed in CNS
inflammation, were associated with increased plasma viral load during acute and chronic infection. Evidence of
neuronal injury in the basal ganglia was associated with increased plasma viral load in the chronic stage of infection.
These observations support the use of drugs capable of controlling the viral replication and trafficking of virus into
the CNS, and may help explain the reduction in incidence of HIV-associated dementia in the era of HAART
despite the inability of most of those drugs to effectively enter the CNS.
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Background
The pathogenesis of brain injury in HIV infection remains
incompletely understood. Elucidation of the pathogenesis
of HIV brain injury is confounded by major uncertainties
in humans, such as time of infection, variable treatments,
and lack of access to brain tissue for evaluation. Neuroim-
aging has helped in understanding HIV related brain
injury, and in recent years in vivo 1H MR spectroscopy has
emerged as amongst the most informative method [1-11].
Brain MRS abnormalities in HIV have been widely
reported, but studies have been limited to the chronic
stages of HIV infection. To our knowledge, only one lon-
gitudinal MRS study of untreated, chronically HIV
infected subjects have been reported [12]. Brain abnor-
malities that may occur during the acute and subacute
stages as well as their relationship to chronic HIV infec-
tion are unknown.
The SIV-infected macaque is an excellent animal model
for studying the neuropathogenesis of HIV-related brain
injury [13,14], and 1H MRS may be used repeatedly in the
same animal to follow brain abnormalities from early to
late stages. In vivo macaque brain 1H MR spectra are simi-
lar to humans [14], and post mortem MRS studies from SIV-
infected macaques have revealed metabolic abnormalities
similar to those observed in chronically HIV-infected
human brains by in vivo MRS [15,16]. Significantly, cere-
bral injury is observed by in vivo 1H MRS [17] as well as by
in vitro 1H MRS and neuropathology shortly after SIV
infection [15,16]. It is not known whether full recovery
occurs, or whether these cerebral abnormalities persist
into the subacute and chronic periods. One puzzle is that
while virtually all SIV-infected macaques demonstrate cer-
ebral injury acutely, fewer than a third ultimately develop
SIV encephalitis (SIVE) [18].
Our previous observations of early brain injury in the SIV-
infected macaque led to the investigation reported here
[15,16]. Our previous MRS studies were performed only
on post mortem frontal cortex samples using solution 1H
MRS of brain extracts [15] or high resolution magic angle
spinning 1H MRS and neurohistochemistry of brain tissue
samples [16]. Those studies revealed evidence of frontal
cortex neuronal injury with declines of the MRS neuronal
marker N-acetylaspartate (NAA) [15,16], and the neuro-
histochemcial neuronal markers synaptophysin and calbi-
ndin. [16] An important limitation of this previous work
was that the brain samples were only from animals that
had been euthanized within 2 weeks of infection, or at ter-
minal AIDS. Thus, the events that may occur in the brain
and are detectable by MRS between the very early and late
periods of infection were unknown, and form, in part, the
rationale for the present study design. Another issue aris-
ing from our previous in vitro studies was that we failed to
detect expected increases in the choline-containing com-
pounds (Cho) and myo-inositol (MI) that are commonly
seen HIV infected patients [5-11].
In the study that we report here, we sought to understand
whether brain injury in the SIV-infected macaque is
detectable by in vivo 1H MRS in the subacute and chronic
periods after infection, whether there are metabolic brain
markers that predict the development of SIV encephalitis,
and whether there are relationships between traditional
clinical markers and brain MRS abnormalities. In a cohort
of 8 macaques, we noninvasively evaluated the effect of
SIVmac251 infection on the macaque brain by MRI and
1H MRS in a prospective, longitudinal manner.
Results
The longitudinal in vivo 1H MRS study that we report here
is an extension of a study in which 15 rhesus macaques
were inoculated intravenously with SIVmac251 and
imaged during the first month of infection [17]. Seven of
the animals were euthanized within the first month of
infection, and the remaining 8 macaques were followed
longitudinally until euthanized because of terminal AIDS
or the two-year study endpoint. We define 3 time periods
with respect to infection: acute (within a month), suba-
cute (between 1 and 3 months), chronic periods (beyond
3 months). Details of animal age, survival and pathologi-
cal findings are summarized in Table 1. Two of the 8 ani-
mals developed SIV encephalitis (SIVE) as defined by the
presence of perivascular infiltrates of macrophages and
multinucleated giant cells. Four of the 8 animals where
terminated before 2 years after SIV inoculation due to ter-
minal AIDS. Two of the 4 early-terminated animals were
the ones that also had SIVE. The other 2 animals that were
terminated early had evidence of mild CNS pathology,
but not SIVE. Four macaques survived to the designated
two-year end point, and none displayed CNS pathology.
Obvious neurological deficits such as paralysis or seizures
were not observed in any of the animals by the veterinar-
ians caring for the animals. Formal neurological examina-
tions were not performed.
Serial MR imaging and spectroscopy studies were per-
formed before and after SIV inoculation on a clinical MR
instrument (1.5 T). A total of 57 scans were performed on
the cohort. The number of scans that were performed in
an individual animal varied from 4 to 10 scans, depend-
ing on time of survival. A neuroradiologist reviewed all
brain MR images. No brain MRI abnormalities such as
masses, abscesses, fluid collections, hemorrhage, white
matter signal abnormalities or infarcts were detected in
any animal before or at any time after SIV infection. In vivo
1H MR spectroscopy was performed using a protocol that
has been validated for multicenter studies of HIV infected
patients [11]. We have previously reported the details of
the normal macaque brain MR spectrum that is very sim-BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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ilar to the human brain MR spectrum [14]. An axial T2
weighted MR image demonstrating frontal lobe voxel
placement, and an MR spectrum from that location is
shown in figure 1. The macaque brain MR spectrum dem-
onstrates high quality in terms of spectral resolution and
signal-to-noise ratio, and is similar to human MRS data
obtained using the same protocol [11].
We examined changes in the brain in MRS resonances
commonly designated as N-acetylaspartate (NAA),
choline (Cho), myoinositol (MI) and creatine (Cr). MR
spectra were obtained from the frontal cortex, centrum
semiovale and basal ganglia, before infection and at mul-
tiple time points after infection. The time points include 2
weeks, 4 weeks, 3 months, 13 months, 15 months, 17
months, 19 months and 24 months post inoculation (pi).
The average values from all animals imaged at each time
point for the major metabolite ratios from each anatomic
location acquired across the duration of the study are dis-
played in figures 2, 3 and 4. While each animal was
scanned for up to 2 years, the study took place over 3
years. Instrumental stability was confirmed through anal-
ysis of MRS data from a phantom containing NAA, Cr,
Cho and MI acquired the same day as the animal studies.
Across the 3 years of the study, the standard deviation of
the phantom Cho/Cr was 2.7%, the NAA/Cr standard
deviation was 3.0%, and the MI/Cr standard deviation
was 5.8%. Regression analysis demonstrated a slope of
<0.001% for each metabolite ratio versus time, i.e., there
was no detectable change over time in phantom metabo-
lite ratios. These data confirm instrumental stability across
the 3 year duration of the study.
We found in this cohort a significant increase in frontal
lobe Cho/Cr 2 weeks post inoculation (p < 0.05), a time
coincident with viral neuroinvasion and increased num-
bers of perivascular macrophages [5,19,20]. These
changes were also observed in the entire 15 animal cohort
of the acute SIV infection study [17]. This was followed by
a decrease to below baseline at four weeks post inocula-
tion (p < 0.01) as shown in figure 2. Subsequent to the
acute period, some variation in Cho/Cr with time is
apparent in figure 2, but we found no statistically
significant difference between pre-infection mean values
and any other post infection time point mean values in
any of the brain regions. We did not detect statistically sig-
nificant differences in NAA/Cr (figure 3) and MI/Cr (fig-
ure 4) in any of the brain regions under investigation after
SIV infection compared to pre-infection values at any time
point. In the 15 animal cohort studied during the first
month after SIV infection, we detected statistically signifi-
cant transient decline in NAA/Cr and an elevation in MI/
Cr in the frontal cortex. [17] Restricting data analysis to
the 8 animals followed longitudinally did not provide
sufficient statistical power to detect significant changes in
NAA/Cr or MI/Cr.
Table 1: SIV-infected macaque clinical and histopathological data
Animal Sex Survival Age at death SIVE Reason for euthanasia CNS histopathology Non-CNS pathology
530–98 M 523 dpi 1119 days est Y Weight loss; mild 
diarrhea
Moderate SIVE; 
meningo-
encephalomyelitis due 
to CMV
Orchitis due to CMV; 
enterotyphlocolitis
456–98 F 176 dpi 948 days Y Weight loss; severe 
diarrhea
Mild SIVE SIV giant cell 
pneumonia and PCP; 
mild enteritis
526–98 M 153 dpi 756 days est N Weight loss; diarrhea; 
anorexia
Mild perivascular 
accumulations of 
macrophages
Mild PCP and CMV in 
lung; 
glomerulonephritis
520–98 M 293 dpi 1254 days est N Severe oral disease Mild perivascular 
edema
Ulcerative gingivitis and 
osteomyelitis; 
myocarditis
202–98 M 742 dpi 1648 days N Epistaxis; respiratory 
disease
No significant CNS 
pathology
Severe PCP
513–98 F 726 dpi 1694 days est N Termination of study No significant CNS 
pathology
Vegetative 
endocarditis; fibrinous 
pleuritis
104–98 F 735 dpi 1646 days N Termination of study No significant CNS 
pathology
Mild enteritis
170–98 F 735 dpi 1612 days N Termination of study No significant CNS 
pathology
Vegetative 
endocarditis; severe 
protozoal gastritis
SIVE: SIV encephalitis CNS: central nervous system CMV: Cytomegalovirus PCP: Pneumocystis carinii pneumonia dpi: days post-inoculation est: 
estimatedBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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A major goal of this study was to investigate whether there
are metabolic brain markers that predict the development
of SIV encephalitis. We found that there was a significant
difference in the Cho/Cr ratio in the basal ganglia (p =
0.022) between encephalitic and non-encephalitic ani-
mals at four weeks post-inoculation as shown in figure 5.
In both groups of animals there was an initial rise in Cho/
Cr within 2 weeks of infection, but the elevated levels per-
sisted at 4 weeks only in those animals that eventually
developed encephalitis. In all other animals, the Cho/Cr
Representative in vivo 1H MR spectrum from the frontal lobe Figure 1
Representative in vivo 1H MR spectrum from the frontal lobe. The spectrum was obtained from the location indicated in the fig-
ure inset and measures 1.5 × 1.5 × 1.5 cm3. The spectrum was acquired using a PRESS sequence (TE = 35 msec, TR = 3000 
msec) with CHESS water suppression. Displayed on the spectrum are the metabolites utilized for the study and include NAA 
(N-acetylaspartate), Cho (choline-containing metabolites), Cr (creatine + phosphocreatine) and MI (myo-inositol).BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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Longitudinal cerebral Cho/Cr ratios in SIV-infected macaques Figure 2
Longitudinal cerebral Cho/Cr ratios in SIV-infected macaques. Data were derived from MR spectra from 3 cerebral locations. 
BG represents scans taken in the basal ganglia region, FC represents scans taken in the frontal cortex, and CS represents scans 
taken from the centrum semiovale. Error bars represent the standard error of the mean (SEM). Asterisks represent statistically 
significant metabolite ratio differences compared to pre-infection values. All eight animals were scanned at every time point 
through 90 dpi. After this time: 270 dpi represents 6 animals, 390 dpi 5 animals, 450 dpi 3 animals, 510 dpi 4 animals, 570 dpi 3 
animals, and 720 dpi 4 animals. Cho/Cr values obtained from the frontal cortex were significantly higher than baseline values at 
two weeks post inoculation (* P < 0.05) and was followed by a sharp decline to below baseline at 4 weeks post inoculation (** 
P < 0.01). Cho/Cr in the other regions displayed similar, albeit non-significant changes in the first four weeks following infec-
tion. The inset plot in the Cho/Cr figure expands the first 4 weeks after infection. For all of the regions ANOVA revealed no 
statistically significant changes in the chronic phase of infection (>28 dpi).BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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ratio dropped substantially after the period of peak
viremia (11–13 dpi). After 3 months, however, the Cho/
Cr values of the encephalitic animals were indistinguisha-
ble from those of the non-encephalitic SIV-infected
macaques.
A further goal in this prospective study was to evaluate
relationships between changes in blood/plasma measure-
ments and brain metabolite changes. For this evaluation,
only blood/plasma samples obtained within 24 hours of
scanning were considered. The relationship between a
change in frontal Cho/Cr and plasma viral load is shown
in figure 6a. We observed a significant correlation
between these parameters (p < 0.001, r = 0.80). Evaluating
MRS data collected after the acute phase (>30 days post-
inoculation), a significant negative correlation was found
Longitudinal cerebral NAA/Cr ratios in SIV-infected macaques Figure 3
Longitudinal cerebral NAA/Cr ratios in SIV-infected macaques. Values of NAA/Cr obtained from the three measured regions 
are displayed. ANOVA revealed no significant changes for the three regions. Experimental details and plot legends as in Figure 
2.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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between the change in basal ganglia NAA/Cr and the
plasma viral load (p < 0.02, r = -0.73). This relationship is
illustrated in figure 6b.
We did not detect other correlations between brain
metabolite ratios and other blood/plasma measurements.
In particular, we did not find a correlation between lym-
phocyte subsets (CD4+, CD8+) and brain MRS measure-
ments. However, we did observe substantial variations in
the levels of these lymphocyte subsets over time in the
individual macaques. The most notable changes were
declines in CD4+ lymphocytes to very low levels in the 2
animals that developed SIVE.
Discussion
This is the first longitudinal neuroimaging study of
human or nonhuman primates that begins before infec-
tion by an immunodeficiency virus, and continues
through to the development of encephalitis. In a cohort of
8 rhesus macaques, we serially performed in vivo 1H MR
Longitudinal cerebral MI/Cr ratios in SIV-infected macaques Figure 4
Longitudinal cerebral MI/Cr ratios in SIV-infected macaques. Values of MI/Cr obtained from the three measured brain regions 
are displayed. For the duration of the study ANOVA revealed no significant changes in the ratios for the three brain regions. 
Experimental details and plot legends as in Figure 2.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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spectroscopy and MRI with the goals of demonstrating
whether brain injury in the SIV-infected macaque is
detectable noninvasively, whether there are metabolic
brain markers that predict the development of SIV
encephalitis, and whether there are relationships between
traditional clinical markers and brain 1H MRS
abnormalities. While MRI appeared normal, novel
metabolic abnormalities were observed, and they provide
new insights into the response of the CNS to SIV infection
that are relevant to HIV infection in humans.
The  1H MRS changes seen shortly after infection were
expected. Previous work from our laboratory documented
similar findings by MRS both in vivo [17] and in post mor-
tem studies [15,16]. Our observations during the subacute
and chronic stages of SIV infection are new. Our most
interesting finding was an elevation of Cho/Cr in the basal
ganglia four weeks post-inoculation in the 2 animals des-
tined to develop SIVE, whereas the other 6 animals had
basal ganglia Cho/Cr values below baseline (figure 5).
SIV-induced neuropathological changes are variable with
SIV encephalitis developing in 25% of infected macaques
[18], similar to the incidence of encephalitis in HIV-
infected humans, and the rate of SIVE in the present study.
It is not clear why there is a spectrum of individual
responses to infection with the same virus. The most likely
explanations include viral mutation and the differences in
host factors. Throughout the course of infection there is a
high rate of mutation [21-24]. Our data supports an
important role for host factors; at 4 weeks pi, when mini-
mal viral mutation is expected, we found a clear difference
in the basal ganglia Cho/Cr ratio between those macaques
destined to develop SIVE and the others.
We suggest that the observation of persistent basal ganglia
Cho/Cr elevation during the first month after infection is
a marker of host susceptibility to SIVE. If confirmed, it
may have important implications for design of further
research, and potentially in the clinical management of
patients. To our knowledge, the only other biomarker
with the potential to predict encephalitis is elevated levels
of macrophage chemoattractant protein-1 (MCP-1) in the
CSF for development of SIVE [25]. However, the MCP-1
finding was observed in an accelerated SIVE model that
employs 2 viruses, results in a high rate of SIVE, and is
quite different from the human situation. If persistence of
elevated cerebral Cho/Cr is found to also be a predictor of
a neurocognitive disorder in HIV-infected patients it
could become an important clinical tool. For example, it
may be used to identify individuals that may benefit from
early, CNS-targeted or more aggressive administration of
antiviral, anti-inflammatory, and neuroprotective agents.
Prior studies have demonstrated viral neuroinvasion in
the weeks following infection [20,26]. Brain abnormali-
ties have been documented by in vivo 1H MRS [17], in vitro
1H MRS [15,16], and neuropathology [16] in post-mor-
tem tissues obtained within 2 weeks of infection. In the
present study, we again observed abnormalities in vivo,
specifically, elevation of frontal lobe Cho/Cr at the time of
peak viremia (2 weeks pi), and a diminution of this ratio
to below baseline at 4 weeks pi, after the immune system
responded to the virus. An elevation of Cho/Cr is often
observed in CNS inflammatory processes, and is seen in
HIV infected patients before evidence of neuronal injury
or neurocognitive symptoms [2,4,5,27]. While a marked
astrogliosis was observed in post-mortem tissue [16], ele-
vations of the choline-containing metabolites in the in
vitro MR spectra were not [15,16]. Thus, in vivo Cho/Cr
elevation appears to be related to astrogliosis, but levels of
choline-containing compounds measured by MRS in vitro
do not correlate. These findings are curious, and suggest
Basal ganglia Cho/Cr ratios obtained four weeks after infec- tion in animals that subsequently developed SIV encephalitis  and those that did not Figure 5
Basal ganglia Cho/Cr ratios obtained four weeks after infec-
tion in animals that subsequently developed SIV encephalitis 
and those that did not. Error bars represent the standard 
error of the mean (SEM). A t test was performed assuming 
equal variances between the two groups of animals. A test to 
determine whether the variances between the two groups of 
animals were different proved not to be significant. Animals 
that later were found to have SIVE (encephalitic) (n = 2) had 
higher Cho/Cr compared to the other animals (n = 6) (P = 
0.022).BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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Correlations between the plasma viral load and metabolite ratios in the frontal lobe and basal ganglia Figure 6
Correlations between the plasma viral load and metabolite ratios in the frontal lobe and basal ganglia. All values are changes 
from pre-infection measurements. 6a: Plasma viral load vs. Cho/Cr in the frontal lobe for the entire duration of the study. 
Regression analysis revealed a statistically significant linear correlation (P < 0.001, R = 0.8). 6b: Plasma viral load vs. NAA/Cr for 
the chronic phase of the study (>4 weeks) in the basal ganglia. Regression analysis revealed a statistically significant negative 
correlation (P < 0.02, R = -0.73) The line represents the least squares fit.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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that there is a poorly understood contribution to the Cho
resonance measured by 1H MRS in vivo that requires fur-
ther study.
Our observation of a positive linear correlation between
plasma viral load and changes in frontal Cho/Cr during
both the acute and chronic periods (figure 6a) is a new
finding that may help to illuminate the CNS response to
SIV. The brain viral inflammatory process induced by the
virus may progress in at least 2 ways [28]. The virus may
enter the CNS shortly after infection, and continue to rep-
licate there, producing a chronic, progressive inflamma-
tory process that ultimately leads to neurodegeneration.
Alternatively, virus may be largely cleared from the CNS
after the initial viremia is controlled by the immune
system, and cerebral inflammation returns only when
there is loss of immunological control and recurrence of
viremia. Our findings illustrated in figure 6a support a
third proposition: brain inflammation tracks, and is
directly related to blood levels of the virus which may
peak from time to time, even before the onset of AIDS.
We did not detect reduced NAA/Cr as a function of time
after infection in this longitudinal study (figure 3). We
have previously observed declines in NAA/Cr 2 weeks
after infection using in vivo [17] and in vitro 1H MRS
[15,16]. The most likely explanation is that SIVE was
infrequent, and CNS disease was mild on average across
the 8 animals. Thus NAA changes were too subtle to be
detected in this small cohort by in vivo 1H MRS at 1.5 T.
Indeed in our previous in vivo 1H MRS study [17], we
found changes in NAA at 2 weeks, but a total of 15 ani-
mals were studied. This conclusion is also supported by
human studies. The imaging protocol we employed in this
study is identical to one used in a multicenter study of HIV
infected subjects [11]. That study detected a small differ-
ence in NAA/Cr, but required 15 HIV- and 38 neurosymp-
tomatic, HIV+ subjects [11]. Other in vivo MRS human
studies demonstrating decreased NAA/Cr performed at
1.5 T also employed larger numbers and more advanced
disease [1-3,6,8,10,27,29,30].
Variable progression of CNS disease in individual pri-
mates may also explain our inability to detect NAA/Cr
change as a function of time after infection. If CNS injury
in AIDS is characterized by different rates of neuronal
injury progression alternating with periods of remission,
the averaging of measurements at specific time points
within a small cohort would mask evidence of brain
injury. We mitigated the effects of temporal averaging by
comparing brain metabolite levels with plasma viral load
in individual animals, and found evidence of brain injury
in the subacute and chronic periods of infection. As illus-
trated in figures 6a and 6b, SIV viremia significantly corre-
lated with elevated frontal lobe Cho/Cr and decreased
basal ganglia NAA/Cr. These correlations between plasma
viral load and brain metabolites during the chronic phase
of SIV infection suggests that CNS injury is dependent on
the presence of the virus, most likely transmitted into the
CNS by the trafficking of SIV-infected monocytes [19,31-
33].
The issue of variable response by different brain regions in
response to SIV infection merits comment. Such variation
in HIV-infected individuals has been reported by many
groups [4-11]. We also find regional variations in the SIV
infected macaque brain. We found that at 2 weeks pi the
changes in Cho/Cr ratio appear greater in the frontal cor-
tex than other areas. We do not know the situation in the
human condition because such studies have not been
reported in the early post infection stage. After the 2 week
period, neuronal injury was more evident in basal ganglia
than in other brain regions in the macaque, similar to
human studies [11]. It is possible that the tropism of the
virus may change with time. That is, it is possible that
early metabolic changes are prominent in the cortical
regions and only later are they more prominent in the
basal ganglia.
Conclusions
We monitored the brains of SIV-infected rhesus macaques
with in vivo 1H MR spectroscopy longitudinally for up to
two years. While no MRI abnormalities were detected,
metabolic changes were observed by MRS. During the first
2 weeks of infection, we observed stereotypical brain MRS
abnormalities. Thereafter we found a divergence in brain
metabolic patterns amongst the animals. We found that
an elevation of Cho/Cr in the basal ganglia four weeks
after inoculation identified animals destined to develop
SIVE, an observation that may have important clinical
implications. Beyond the 2 week post inoculation, we did
not find statistically significant differences in metabolite
ratios averaged across all 8 animals between baseline and
any specific time point. Yet we found a statistically signif-
icant positive correlation between frontal cortex Cho/Cr
and viral load, and a statistically significant negative cor-
relation between basal ganglia NAA/Cr and viral load.
Thus, both elevations of the Cho/Cr ratio, often observed
in CNS inflammatory processes, and evidence of neuronal
injury, reduced NAA/Cr, were associated with increased
plasma viral load. These observations indicate brain met-
abolic changes in the SIV infected macaque are driven by
plasma viral load, and not by time after infection. Our
findings that metabolic indicators of both cerebral inflam-
mation and neuronal injury correlate with viral levels in
the periphery also underscore the need to employ thera-
peutic regimens capable of controlling the propagation
and trafficking of virus into the CNS. It may also help
explain the reduction in incidence of HIV-associatedBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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dementia in the era of HAART despite the inability of
most of those drugs to effectively enter the CNS.
Materials and methods
Animals and viral inoculation
Eight juvenile rhesus macaques (Macaca mulatta) were
inoculated intravenously with SIVmac251 (50 ng p27/kg)
[34]. Animals were housed at the New England Primate
Research Center, Southborough, MA and transported to
the MGH NMR Center, Charlestown, MA for imaging. In
preparation for imaging, the animals were initially tran-
quilized with ketamine or telazol and anesthetized with
sodium pentobarbital. All animals were housed according
to the standards of the American Association for Accredi-
tation of Laboratory Animal Care. Investigators abided by
the Guide for the Care and Use of Laboratory Animals of
the Institute of Laboratory Animal resources, National
Research Council. Animals were euthanized by an over-
dose of sodium pentabarbitol when they reached terminal
AIDS or at the 2-year end point of the study. Postmortem
pathological examinations were performed on all ani-
mals. The determination of encephalitis was based upon
the presence of perivascular macrophages and multinucle-
ated giant cells in the brain and detection of viral nucleic
acids by in situ hybridization of three different brain
regions, as described below.
Magnetic resonance imaging and spectroscopy
Each macaque had MRI and MRS performed before infec-
tion, and at multiple time points after being inoculated
with SIVmac251. All macaques were scanned at 2 weeks
post inoculation (11 days post inoculation (dpi) or 13
dpi), 4 weeks post inoculation (25 dpi or 27 dpi), 3
months post inoculation (mpi), 13 mpi, 15 mpi, 17 mpi,
19 mpi and 24 mpi. Since no study of this type had ever
been reported, the rationale for this imaging schedule was
based on our previous limited investigations of post mor-
tem brain samples [15,16]. We define 3 time periods with
respect to infection: acute (within a month), subacute
(between 1 and 3 months), chronic periods (beyond 3
months). Brain imaging was performed on a clinical 1.5
Tesla General Electric (Milwaukee, Wisconsin) Signa scan-
ner with operating system Horizon 5.6 or 8.3, and a linear
extremity coil.
The MRI portion of the exam consisted of T1 weighted
sagittal images, followed by dual-echo, proton-density
and T2 weighted axial images. Axial images were used to
localize a 1.5 cm × 1.5 cm × 1.5 cm spectroscopy voxel in
3 locations: frontal cortex with the voxel centered on the
interhemispheric fissure; deep white matter with the voxel
centered on centrum semiovale; and basal ganglia with
the voxel centered on the putamen. On repeat imaging,
the animal head was positioned as in the previous study
using three-plane scout imaging and iterative reposition-
ing. In this manner, voxel placement was highly reproduc-
ible. With the exception of a slightly smaller voxel size, the
MR spectroscopy protocol was identical to the one
employed in multicenter human HIV studies that is char-
acterized by high intersite and temporal reproducibility
[11].
After animal imaging, MRS was performed on a phantom
containing known concentrations of major brain metabo-
lites (N-acetylaspartate, creatine, choline and myo-inosi-
tol). Phantom MR spectral data was employed to assess
instrument stability. The protocol uses automated
PROBE-P spectroscopy package, which consists of a PRESS
sequence (TE = 35 msec, TR = 3000 msec) with CHESS
water suppression [35,36].
All spectra were processed off-line with the SAGE-GE spec-
tral analysis program [37] to determine intensities of N-
acetylaspartate (NAA), choline-containing compounds
(Cho), and myoinositol (MI) resonances, relative to the
creatine/phosphocreatine (Cr) resonance which served as
internal intensity reference.
Plasma viral loads
Virion associated SIV RNA in plasma was quantified by
using a real-time reverse transcription-PCR assay on an
Applied Biosystems Prism 7700 sequence detection sys-
tem as described previously [38,39]. Results are averages
of duplicate determinations. Analyses of viral RNA levels
were performed by Drs. Jeffrey Lifson and Michael Piatak
at SAIC-Frederick.
In situ hybridization
We examined frontal cortex, basal ganglia, and hippocam-
pus/temporal cortex by SIV riboprobe in situ hybridiza-
tion (ISH) for viral nucleic acid, as previously described
[19,40]. The ISH utilizes a DIG-labeled antisense ribo-
probe provided by Drs. V. Hirsch and C. Brown (National
Institutes of Health, Rockville, MD) [41]. Tissues were
microwave pretreated and hybridized overnight at 45°C
with 10 ng of antisense riboprobe. Hybridized probe was
detected with alkaline phosphatase-conjugated anti-DIG
antibody using standard immunologic methods. Controls
consisted of sense probes, which had been labeled with
digoxigenin at the same time as the anti-sense probe, and
matched tissues from uninfected, age-matched control
macaques.
Flow cytometry
Lymphocytes were isolated from blood and stained for
flow cytometric analysis as previously described [42].
Samples were immunoreacted with monoclonal antibod-
ies against human CD4 (Ortho Diagnostics), CD8 (Bec-
ton Dickinson), and anti-rhesus CD3 (courtesy of J.
Wong, Mass General Hospital) directly conjugated toBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/10
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either FITC, PE, PerCP, or APC. Samples were analyzed
using a Vantage flow cytometer and Cell Quest Software
(Becton Dickinson).
Statistical analysis
T tests assuming equal variances were used in compari-
sons between encephalitic and non-encephalitic animals.
Prior to this, the validity of assuming equal variances was
assessed. Correlations between cerebral metabolite ratios,
flow cytometry, and SIV plasma viral load were calculated
by regression analysis after adjusting all values relative to
baseline measurements. Additionally ANOVA and Stu-
dent-Newman-Keuls tests were utilized for the determina-
tion of trends.
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